Literature DB >> 6846235

Bioavailability of selenium to Finnish men as assessed by platelet glutathione peroxidase activity and other blood parameters.

O A Levander, G Alfthan, H Arvilommi, C G Gref, J K Huttunen, M Kataja, P Koivistoinen, J Pikkarainen.   

Abstract

Three groups of 10 men of low selenium status were given 200 micrograms Se/day as Serich wheat, Se-rich yeast, or sodium selenate for 11 wk. Twenty unsupplemented subjects served as controls. Plasma Se levels increased steadily in the wheat and yeast groups for 11 wk without plateauing, whereas in the selenate group, plasma Se plateaued around 110 ng/ml after 4 wk. Platelet glutathione peroxidase (GSH-Px) activities increased rapidly in the wheat and selenate groups for 4 wk and then plateaued. Platelet GSH-Px increased more slowly in the yeast group. Ten weeks after the supplements were discontinued, platelet GSH-Px was higher in the wheat and yeast groups than in the selenate group. Assessment of Se bioavailability requires a short-term platelet GSH-Px measurement to determine immediate availability, a medium-term plasma Se measurement to estimate retention, and a long-term platelet GSH-Px measurement after supplements are discontinued to determine the covertibility of tissue Se stores to biologically active Se.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6846235     DOI: 10.1093/ajcn/37.6.887

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  21 in total

Review 1.  Selenium metabolism and bioavailability.

Authors:  L A Daniels
Journal:  Biol Trace Elem Res       Date:  1996-09       Impact factor: 3.738

2.  Effect of selenium and vitamin E supplements on tissue lipids, peroxides, and fatty acid distribution in experimental diabetes.

Authors:  C Douillet; M Bost; M Accominotti; F Borson-Chazot; M Ciavatti
Journal:  Lipids       Date:  1998-04       Impact factor: 1.880

3.  A comparison of selenomethionine and sodium selenite as a supplement in chicken feeds.

Authors:  K Moksnes; G Norheim
Journal:  Acta Vet Scand       Date:  1986       Impact factor: 1.695

4.  Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: a placebo-controlled, double-blind study of selenomethionine supplementation in selenium-deficient Chinese subjects.

Authors:  Yiming Xia; Kristina E Hill; Ping Li; Jiayuan Xu; Dingyou Zhou; Amy K Motley; Li Wang; Daniel W Byrne; Raymond F Burk
Journal:  Am J Clin Nutr       Date:  2010-06-23       Impact factor: 7.045

5.  Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial.

Authors:  William G Christen; Robert J Glynn; J Michael Gaziano; Amy K Darke; John J Crowley; Phyllis J Goodman; Scott M Lippman; Thomas E Lad; James D Bearden; Gary E Goodman; Lori M Minasian; Ian M Thompson; Charles D Blanke; Eric A Klein
Journal:  JAMA Ophthalmol       Date:  2015-01       Impact factor: 7.389

Review 6.  Selenium and cancer: biomarkers of selenium status and molecular action of selenium supplements.

Authors:  Jolanta Gromadzińska; Edyta Reszka; Katharina Bruzelius; Wojciech Wasowicz; Björn Akesson
Journal:  Eur J Nutr       Date:  2008-05       Impact factor: 5.614

7.  Is serum selenium a risk factor for cancer?

Authors:  I Peleg; S Morris; C G Hames
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

8.  Glutathione and selenium in rheumatoid arthritis.

Authors:  T Möttönen; P Hannonen; O Seppälä; G Alfthan; M Oka
Journal:  Clin Rheumatol       Date:  1984-06       Impact factor: 2.980

9.  Correlation between selenium concentrations and glutathione peroxidase activity in serum and human prostate tissue.

Authors:  Yumie Takata; J Steven Morris; Irena B King; Alan R Kristal; Daniel W Lin; Ulrike Peters
Journal:  Prostate       Date:  2009-11-01       Impact factor: 4.104

10.  Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis.

Authors:  B A Lashner
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.